Show simple item record

dc.contributor.authorBalbay, Yucel
dc.contributor.authorGagnon-Arpin, Isabelle
dc.contributor.authorMalhan, Simten
dc.contributor.authorOksuz, Mehmet Ergun
dc.contributor.authorSutherland, Greg
dc.contributor.authorDobrescu, Alexandru
dc.contributor.authorVilla, Guillermo
dc.contributor.authorErtugul, Gulnihal
dc.contributor.authorHabib, Modhar
dc.date.accessioned2020-12-15T13:08:34Z
dc.date.available2020-12-15T13:08:34Z
dc.date.issued2019
dc.identifier.issn1016-5169en_US
dc.identifier.urihttps://archivestsc.com/jvi.aspx?un=TKDA-40330
dc.identifier.urihttp://hdl.handle.net/11727/5070
dc.description.abstractObjective: Our study aimed to estimate the impact of addressing modifiable risk factors on the future burden of cardiovascular diseases (CVD) in the general population and in two high-risk populations (heterozygous familial hypercholesterolemia and secondary prevention) for Turkey. Methods: One model investigated the impact of reaching the World Health Organization (WHO) voluntary targets for tobacco use, hypertension, type 2 diabetes, obesity and physical inactivity in the general population. Another model estimated the impact of reducing LDL-cholesterol in two high-risk populations through increased access to effective treatment. Inputs for the models include disease and risk factor prevalence rates, a population forecast, baseline CVD event rates, and treatment effectiveness, primarily derived from the published literature. Direct costs to the public health care system and indirect costs from lost production are included, although the cost of programs and pharmacological interventions to reduce risk factors were not considered. Results: The value of reaching WHO risk factor reduction targets is estimated at US$9.3 billion over the next 20 years, while the value of reducing LDL-cholesterol is estimated at up to US$8.1 billion for high-risk secondary prevention patients and US$691 million for heterozygous familial hypercholesterolemia patients. Conclusion: Efforts to achieve WHO risk factor targets and further lower LDL-cholesterol through increased access to treatment for high-risk patients are projected to greatly reduce the growing clinical and economic burden of CVD in Turkey.en_US
dc.language.isoengen_US
dc.relation.isversionof10.5543/tkda.2019.40330en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCardiovascular diseasesen_US
dc.subjectheart diseasesen_US
dc.subjecthyperlipidemiasen_US
dc.subjectpublic healthen_US
dc.subjectrisk factorsen_US
dc.titleThe impact of addressing modifiable risk factors to reduce the burden of cardiovascular disease in Turkeyen_US
dc.typearticleen_US
dc.relation.journalTURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGYen_US
dc.identifier.volume47en_US
dc.identifier.issue6en_US
dc.identifier.startpage487en_US
dc.identifier.endpage497en_US
dc.identifier.wos000484379600009en_US
dc.identifier.scopus2-s2.0-85071767954en_US
dc.contributor.pubmedID31483303en_US
dc.contributor.orcID0000-0002-5723-5965en_US
dc.contributor.researcherIDK-8238-2012en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record